FTC puts conditions on Lupin and Hikma acquisitions

21 February 2016

The US Federal Trade Commission was seen to flex its muscles on Friday, as it imposed conditions on two proposed M&A deals.

Indian generic drug manufacturer Lupin (BSE: 5002571) and GAVIS Pharmaceuticals will sell the rights and assets for two generic drugs, one used to treat bacterial infections and the other to for ulcerative colitis, in order to settle FTC charges that Lupin’s planned $850 acquisition of USA-based GAVIS would likely be anticompetitive (hr Pharma Letter July 23, 2015).

The proposed consent order preserves competition by requiring the companies to divest these products to the New Jersey, USA-based generic pharmaceutical company G&W Laboratories.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK